Publications by authors named "Ludmila Vologzanina"
Article Synopsis
- A study examined how different reasons for testing for Helicobacter pylori (H. pylori) affect treatment prescriptions and their success rates across Europe from 2013 to 2023.
- Out of 53,636 cases, the most common reasons for testing included dyspepsia with normal endoscopy and various types of ulcers, with treatment effectiveness ranging from 87% to 91% based on the indication.
- Patients with ulcers and preneoplastic lesions experienced higher treatment success and compliance, while those tested for dyspepsia had higher rates of adverse effects.
Background: Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy.
Objective: To determine which factors influence compliance with treatment.
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Manuel Pabón-Carrasco Alma Keco-Huerga Manuel Castro-Fernández Ilaria Maria Saracino Giulia Fiorini Ludmila Vologzanina
United European Gastroenterol J
February 2024
Article Synopsis
- - The management of Helicobacter pylori infection involves a combination of proton pump inhibitors (PPIs) and antibiotics to effectively eradicate the bacteria, as evaluated by the European Registry on Helicobacter pylori management (Hp-EuReg).
- - Analysis of data from 36,579 patients across five countries revealed that 14-day treatments with specific antibiotic combinations and high-dose PPIs resulted in optimal effectiveness, while 10- and 14-day therapies with high-dose PPIs were also successful.
- - The study concludes that for first-line treatment, the use of high-dose PPIs is recommended, especially in certain combinations and durations, while shorter 7-day therapies showed suboptimal results.
Article Synopsis
- Antibiotic resistance significantly affects the treatment success rates for Helicobacter pylori infections, with noted resistance levels in Europe.
- A study analyzed 2,852 naive patients and found that the 3-in-1 single capsule with bismuth, metronidazole, and tetracycline, as well as a quadruple therapy with bismuth, had the highest effectiveness against H. pylori, even with existing resistances.
- For non-naive patients, resistance was even higher, but the same 3-in-1 capsule and triple therapy with levofloxacin showed promising results, highlighting the need for effective treatment options based on resistance patterns.
The prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment.
View Article and Find Full Text PDF